Here are five things to know:
1. In North America, the orthobiologics market is expected to reach more than $3 billion by 2027.
2. The bone graft stimulators segment holds the largest market share and is expected to exceed $3 billion by 2027.
3. The increasing incidence of fracture-causing orthopedic disorders and sports injuries, as well as the rising demand for outpatient surgical procedures and increasing medical tourism, are driving the global orthobiologics market forward.
4. The high cost of orthopedic surgery and increasing competition leading to price fluctuations are limiting the global market’s growth.
5. Key players in the global orthobiologics market include:
- Medtronic
- NuVasive
- Stryker
- Zimmer Biomet
- Orthofix
More articles on biologics:
Kuros Biosciences appoints 5 spine surgeons to advisory board
Orthopedic surgeon named Reinvent Biologics’ CMO: 3 insights
Human skeletal stem cells identified, may have therapeutic potential: 4 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
